Cargando…

Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELD(TM) and COVAXIN(®) induced immunity in COVID-19 exposed Indians

Detailed characterisation of immune responses induced by COVID-19 vaccines rolled out in India: COVISHIELD(TM) (CS) and COVAXIN® (CO) in a pre-exposed population is only recently being discovered. We addressed this issue in subjects who received their primary series of vaccination between November 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rakshit, Srabanti, Babji, Sudhir, Parthiban, Chaitra, Madhavan, Ramya, Adiga, Vasista, J, Sharon Eveline, Chetan Kumar, Nirutha, Ahmed, Asma, Shivalingaiah, Sudarshan, Shashikumar, Nandini, V, Mamatha, Johnson, Avita Rose, Ramesh, Naveen, B, Ramkrishna Goud, Asokan, Mangaiarkarasi, Mayor, Satyajit, Kang, Gagandeep, D’souza, George, Dias, Mary, Vyakarnam, Annapurna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502007/ https://www.ncbi.nlm.nih.gov/pubmed/37709772 http://dx.doi.org/10.1038/s41541-023-00731-w

Ejemplares similares

BCG revaccination qualitatively and quantitatively enhances SARS-CoV-2 spike-specific neutralizing antibody and T cell responses induced by the COVISHIELD(™) vaccine in SARS-CoV-2 seronegative young Indian adults
por: Rakshit, Srabanti, et al.
Publicado: (2022)

Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults
por: Rakshit, Srabanti, et al.
Publicado: (2022)

BCG revaccination in adults enhances pro-inflammatory markers of trained immunity along with anti-inflammatory pathways
por: Ahmed, Asma, et al.
Publicado: (2023)

Differences in Immune Responses in Individuals of Indian and European Origin: Relevance for the COVID-19 Pandemic
por: Geckin, Büsra, et al.
Publicado: (2023)

Circulating Mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL10(+) Th17 CD4 T-cells differentiate latent from active tuberculosis
por: Rakshit, Srabanti, et al.
Publicado: (2017)

“Covishield and Covaxin” – India's contribution to global COVID-19 pandemic
por: Raina, Sunil Kumar, et al.
Publicado: (2021)

Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
por: Das, Swarnali, et al.
Publicado: (2022)

Comparison of in-hospital COVID-19 related outcomes between COVISHIELD and COVAXIN recipients
por: Suri, Tejas M., et al.
Publicado: (2022)

Adverse effects after first and second dose of covishield and covaxin: A longitudinal study
por: Mittal, Amit, et al.
Publicado: (2022)

2371. A study to describe the pattern of cutaneous adverse effects of COVID-19 vaccines (Covishield and Covaxin )
por: Mitra, Debdeep, et al.
Publicado: (2023)

Effectiveness of Covid-19 vaccines (Covishield(TM) and Covaxin (®)) in healthcare workers in Mumbai, India: A retrospective cohort analysis
por: Contractor, Aashish, et al.
Publicado: (2022)

Innate immune mechanisms to oral pathogens in oral mucosa of HIV-infected individuals
por: Weinberg, Aaron, et al.
Publicado: (2020)

Hydrogen sulfide blocks HIV rebound by maintaining mitochondrial bioenergetics and redox homeostasis
por: Pal, Virender Kumar, et al.
Publicado: (2021)

Prevalence, severity, and risk factor of breakthrough infection after vaccination with either the Covaxin or the Covishield among healthcare workers: A nationwide cross-sectional study
por: Krishna, Bhavya, et al.
Publicado: (2022)

Estimation of SARS-CoV-2 IgG Antibodies in Healthcare Worker-Administered Covishield and Covaxin Vaccines at a Tertiary Care Hospital in Jharkhand, India
por: Singh, Bishnupati, et al.
Publicado: (2023)

Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study
por: Rose, Winsley, et al.
Publicado: (2023)

Circulating HLA-DR(+)CD4(+) effector memory T cells resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis
por: Ahmed, Asma, et al.
Publicado: (2018)

Covaxin-Induced Lymphocytic Myocarditis
por: Mittal, Nitish, et al.
Publicado: (2022)

Herpes Zoster Following Covaxin Receipt
por: Muhie, Oumer Abdu, et al.
Publicado: (2021)

Impact of prior vaccination with Covishield(TM) and Covaxin® on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study
por: Abhilash, Kundavaram Paul Prabhakar, et al.
Publicado: (2022)

Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152)
por: Munigela, Apoorva, et al.
Publicado: (2022)

Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India
por: Satpathi, Partha Sarathi, et al.
Publicado: (2022)

WCN23-0557 Higher pro-inflammatory cytokines are associated with anti-SARS-CoV-2 spike protein-specific seroconversion after two doses of COVAXIN™, COVISHIELD™ vaccination in renal transplant recipients
por: Prasad, N., et al.
Publicado: (2023)

Evaluating Cellular Polyfunctionality with a Novel Polyfunctionality Index
por: Larsen, Martin, et al.
Publicado: (2012)

Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study
por: Bhatnagar, Tarun, et al.
Publicado: (2022)

Covaxin: An overview of its immunogenicity and safety trials in India
por: Sharma, Rohit, et al.
Publicado: (2021)

Falsified COVISHIELD products in India and Uganda
Publicado: (2021)

Inactivated vaccine Covaxin/BBV152: A systematic review
por: Ahmed, Tousief Irshad, et al.
Publicado: (2022)

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model
por: Yadav, Pragya D., et al.
Publicado: (2022)

Pityriasis Rosea Following Covaxin (BBV152) Vaccination for COVID-19
por: Singh, Bhabani S. T. P., et al.
Publicado: (2022)

Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center
por: Prasad, Narayan, et al.
Publicado: (2022)

Covid-19 vaccine (covishield) heralding Moyamoya angiopathy()()()
por: Das, Shambaditya, et al.
Publicado: (2022)

Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)®) and BBV-152 (Covaxin(TM)®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Innate immunity against HIV: a priority target for HIV prevention research
por: Borrow, Persephone, et al.
Publicado: (2010)

Neutralisation and the brickwall
por: Hereward, H G
Publicado: (1974)

Covishield vaccine induces robust immune responses in Bangladeshi adults
por: Bhuiyan, Taufiqur Rahman, et al.
Publicado: (2022)

Canadian findings on AstraZeneca COVID-19 Vaccine and COVISHIELD
Publicado: (2021)

Virus Neutralisation: New Insights from Kinetic Neutralisation Curves
por: Magnus, Carsten
Publicado: (2013)

The Self-Assembly and Design of Polyfunctional Nanosystems
por: Kashapov, Ruslan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6iq5ga7msjd2iut8cgr2dgfjvf